BriaCell Therapeutics Corp. Files 8-K: Material Definitive Agreement
Ticker: BCTXZ · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1610820
Sentiment: neutral
Topics: material-definitive-agreement, corporate-event
Related Tickers: BCTX
TL;DR
BriaCell signed a big deal on Oct 1st, filing an 8-K. Details in exhibits.
AI Summary
On October 1, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement, the details of which are not fully disclosed in this filing but are indicated by the filing of exhibits. The company, formerly known as Ansell Capital Corp., is incorporated in British Columbia and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates a significant new agreement for BriaCell Therapeutics, which could impact its future operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former name of registrant
- October 1, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by BriaCell Therapeutics Corp. on October 1, 2024?
The filing indicates a material definitive agreement was entered into on October 1, 2024, but the specific terms and nature of the agreement are not detailed in the provided text, only that exhibits are filed.
When was BriaCell Therapeutics Corp. previously known by another name?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp., with a date of name change on June 13, 2014.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is BriaCell Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
BriaCell Therapeutics Corp.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this Form 8-K?
This Form 8-K was filed on October 2, 2024.
Filing Stats: 1,263 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2024-10-02 16:30:21
Key Financial Figures
- $0.975 — as sold at a combined offering price of $0.975. The Company received aggregate gross
- $5.0 m — eeds from the Offering of approximately $5.0 million, before deducting Placement Agent
- $0.85 — Common Warrant has an exercise price of $0.85 per share, is immediately exercisable f
- $1.21875 — rcisable, and have an exercise price of $1.21875. The Shares, the Common Warrants, the
Filing Documents
- form8-k.htm (8-K) — 62KB
- ex4-1.htm (EX-4.1) — 115KB
- ex4-2.htm (EX-4.2) — 148KB
- ex5-1.htm (EX-5.1) — 26KB
- ex5-2.htm (EX-5.2) — 16KB
- ex10-1.htm (EX-10.1) — 758KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-2.htm (EX-99.2) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 14KB
- ex5-1_002.jpg (GRAPHIC) — 25KB
- ex5-2_001.jpg (GRAPHIC) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- ex99-2_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-039218.txt ( ) — 1683KB
- bctx-20241001.xsd (EX-101.SCH) — 4KB
- bctx-20241001_def.xml (EX-101.DEF) — 29KB
- bctx-20241001_lab.xml (EX-101.LAB) — 36KB
- bctx-20241001_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams October 2, 2024 William V. Williams President and Chief Executive Officer